Glucose-6-phosphatase is required for organelle reorganization, energy metabolism and motility of sperm.

Glucose-6-Phosphatase (G6Pase), a key enzyme in gluconeogenesis and glycogenolysis in the mammalian liver and kidney, converts glucose-6-phosphate to glucose for maintaining systemic blood glucose homeostasis during nutrient deprivation. However, its function has remained elusive in insects, which have no need for G6Pase in sugar homeostasis since they convert glucose-6-phosphate to trehalose, their main circulating sugar, via trehalose phosphate synthase (TPS1). In this study we identify an unexpected and essential requirement for G6Pase in male fertility, specifically to produce motile sperm.

Synthesis and Biological Evaluation of Peripheral HTR2A Antagonists for Colorectal Cancer.

Colorectal cancer is a prevalent and prominent contributor to global cancer-related fatalities with challenges in drug resistance and metastasis. Recent research highlights the potential relationship between serotonin and cancer. 5-Hydroxytryptamine receptor 2A (HTR2A) mRNA expression in colorectal cancer cells was found to be notably elevated compared to that in normal colon cells.

Is the Current Lights-Off Time in General Hospitals Too Early, Given People's Usual Bedtimes?

Objective: This study aimed to investigate how shift-working nursing professionals perceive the current lights-off time in wards as early, appropriate, or late and how their perceptions can be influenced when considering people's usual bedtimes.

Methods: An online survey was conducted comprising queries about the current lights-off time in wards and respondents' opinions, self-rated psychological status, and perceptions of the current lights-off time considering others' usual bedtimes. Psychological status was evaluated using the Insomnia Severity Index, the Patient Health Questionnaire-9, the Dysfunctional Beliefs and Attitudes about Sleep-16, and the Discrepancy between Desired Time in Bed and Desired Total Sleep Time (DBST) Index, along with the expected DBST Index of others.

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world.

Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma.

Background: Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare thoracic tumors of the anterior mediastinum. For those with advanced disease, platinum-based chemotherapy is used as first-line treatment. However, there is no standard regimen established for TET at progression after initial therapy, and treatment options for advanced/recurrent TETs are limited.